C difficile risk
Oral Bioavailability
IV $49/d PO $0.90/d


Defined criteria for use and/or important safety considerations. See below for more information.

750 mg PO/IV q24h

CrCl > 50 mL/minCrCl 20 - 50 mL/minCrCl < 20 mL/minNo renal adjustment required 750 mg PO/IV q48h750 mg PO/IV x 1, then 500 mg PO/IV q48h

750 mg PO/IV x 1, then 500 mg PO/IV q48h

  • Give dose after dialysis on HD days

750 mg PO/IV x 1, then 500 mg PO/IV q48h

750 mg PO/IV x 1, then 500 mg PO/IV q24 - 48h

General Information

Primary - Community Acquired Pneumonia (CAP) requiring ICU admission, Legionella infections

Monitor QTc in patients with increased risk

  • QTc prolongation

  • Dysglycemia

  • Rash

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • CNS toxicity including confusion, psychosis

  • Other QTc prolonging agents

  • Divalent cations - Decreased absorption

  • Warfarin - Increased INR

  • Avoid dairy products, antacids, and other sources of divalent cations (Ca, Fe, Mg, Al, Zn) which can chelate levofloxacin and prevent absorption

  • Must hold continuous tube feeding 2 h before and 2 h after administration.

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 7 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Therapeutic

CSF penetration: Insufficient data

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.